Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a rapamycin-sensitive pathway.
Hindlimb suspension (HS) results in rapid losses of muscle mass, which may in part be explained by attenuated rates of protein synthesis. Mammalian target of rapamycin (mTOR) regulates protein synthesis and has been implicated as a potential mediator of the muscle mass decrement with HS. This study examined the effect of resistance exercise, a muscle hypertrophy stimulant, on rates of protein synthesis after 4 days of HS in mature male Sprague-Dawley rats. Flywheel resistance exercise (2 sets x 25 repetitions) was conducted on days 2 and 4 of HS (HSRE). Sixteen hours after the last exercise bout, soleus muscles were assessed for in vitro rates of protein synthesis, with and without insulin (signaling agonist) and/or rapamycin (mTOR inhibitor). Results demonstrated that soleus mass was reduced (P < 0.05) with HS, but this loss of mass was not observed (P > 0.05) with HSRE. Muscle protein synthesis was diminished (P < 0.05) with HS, with or without insulin. HSRE also had reduced rates of synthesis without insulin; however, insulin administration yielded higher (P < 0.05) rates in HSRE compared with HS or control. Rapamycin diminished protein synthesis in all groups (P < 0.05), but insulin rescued synthesis rates in HS and HSRE to levels similar to insulin alone for each group, suggesting that alternate signaling pathways develop to increase protein synthesis with HS. These results demonstrate that the capacity for an augmented anabolic response to resistance exercise is maintained after 4 days of HS and is independent of a rapamycin-sensitive pathway.
Fluckey
James D
JD
Nutrition, Metabolism and Exercise Laboratory, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 806, Little Rock, AR 72205, USA. Fluckeyjamesd@uams.edu
Dupont-Versteegden
Esther E
EE
Knox
Micheal
M
Gaddy
Dana
D
Tesch
Per A
PA
Peterson
Charlotte A
CA
D000818:Animals; D019417:Hindlimb Suspension; D007328:Insulin / Q000494:pharmacology*; D008297:Male; D009124:Muscle Proteins / Q000096:biosynthesis*; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000502:physiology*; D009929:Organ Size; D005082:Physical Exertion / Q000502:physiology*; D011494:Protein Kinases / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases; D013997:Time Factors
D007328:Insulin; D009124:Muscle Proteins; D011494:Protein Kinases; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus